logo

For the Inventor, By the Inventor

Novato, CA, United States of America

Christopher C Benz

This inventor holds 8 USPTO granted patents and 3 published patent applications. Top assignees: University of California, Buck Institute for Research on Aging. Active years: 1994-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher C Benz. Retrieved from https://idiyas.com/inventor/christopher-c-benz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 62.5

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 147(Granted Patents)


Company Filing History:

goldMedal6 out of 16,025 
 
University of California
 patents
silverMedal2 out of 51 
 
Buck Institute for Research on Aging
 patents

Years Active: 1994-2026

Loading Chart...
8 patents (USPTO):Explore Patents
1. 12714686 - N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders (2026-08-25),
2. 10517844 - Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications (2019-12-31),
3. 7871620 - Immunoliposomes that optimize internationalization into target cells (2011-01-18),
4. 7507407 - Immunoliposomes that optimize internationalization into target cells (2009-03-24),
5. 7135177 - Immunoliposomes that optimize internalization into target cells (2006-11-14),
6. 7125969 - ETS-related gene overexpressed in human breast and epithelial cancers (2006-10-24),
7. 6214388 - Immunoliposomes that optimize internalization into target cells (2001-04-10),
8. 5292638 - Method of determining functional estrogen receptors for prognosis of (1994-03-08),

Title: Christopher C Benz: Innovator in Cancer Treatment and Drug Delivery

Introduction

Christopher C Benz is a notable inventor based in Novato, CA (US), recognized for his contributions to cancer treatment and drug delivery systems. With a total of 8 patents, Benz has made significant strides in the field of medical innovations.

Latest Patents

Benz's latest patents include groundbreaking methods for cancer treatment through the inhibition of proline catabolism. This method combines proline catabolism inhibition with p53 restoration therapy and/or glutaminase inhibition, resulting in a synergistic anticancer response. Additionally, he has developed novel suicide inhibitors that induce the degradation of proline dehydrogenase (PRODH). His work also includes methods for assaying PRODH to identify responders and non-responders to these treatments. Another significant invention is the development of immunoliposomes that optimize the internalization of drugs into target cells. These immunoliposomes are designed to bind to specific cell surface markers, enhancing drug delivery efficiency.

Career Highlights

Throughout his career, Christopher C Benz has worked with prestigious institutions such as the University of California and the Buck Institute for Research on Aging. His research has focused on innovative approaches to cancer therapy and drug delivery, making him a key figure in the field.

Collaborations

Benz has collaborated with notable colleagues, including John W Park and Keelung Hong, contributing to the advancement of his research and inventions.

Conclusion

Christopher C Benz stands out as an influential inventor whose work in cancer treatment and drug delivery continues to impact the medical field. His innovative patents and collaborations reflect his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…